LAROTID
LOE ApproachingNDAORALFOR SUSPENSIONPriority Review
Approved
Jan 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAROTID is an oral suspension small molecule approved in 1974 by GSK. The specific indication and mechanism of action are not publicly detailed in available data, but the oral suspension formulation suggests treatment of an infection or condition requiring pediatric or dysphagic patient dosing.
LOE Approaching
As a 50-year-old product approaching loss of exclusivity, the brand team is likely operating in maintenance mode with minimal resource allocation and flat-to-declining headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LAROTID presents minimal career development opportunity; zero linked job postings reflect a sunset-phase asset. Career mobility into this role is not recommended unless seeking low-stakes legacy product stewardship or transition planning experience.
Brand Manager (legacy)Field Sales (select regions)
Worked on LAROTID at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.